BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Ovarian Cancer

In brief

This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.

Key facts

Study ID

NCT01624493

Run by

Hoosier Cancer Research Network

People needed

0

Starts

2012-10-01

Expected to finish

2014-10-01

Last updated by the study team

2015-12-23

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• University of Chicago — Chicago, Illinois, United States
• Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States
• Royal Prince Alfred Hospital — Sydney, New South Wales, Australia
• Royal Brisbane and Women's Hospital — Brisbane, Queensland, Australia
• Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
• Christchurch Hospital — Christchurch, Canterbury, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.